Missing or incomplete reporting of clinical trial results and its scientific and ethical consequences are well documented. 1, 2 One concrete example of this problem occurs when a sponsor conducts several studies of a particular drug for a particular condition but only some (or none) of the studies make their way into the public domain, leaving a distorted body of public evidence.
3 Policies that require reporting to ClinicalTrials .gov are designed to ameliorate that problem. ClinicalTrials .gov currently has more than 255 000 registered studies, with summary results information for more than 28 000 studies, of which an estimated half lack corresponding publications. 2, 4, 5 To evaluate the influence of this resource on the evidence base, we examined the extent to which sets of trials registered in ClinicalTrials.gov by individual sponsors for the same drug and condition had results available publicly in ClinicalTrials.gov and/or PubMed.
Methods | We identified ClinicalTrials.gov-registered records for industry-sponsored, phase 2 to 4 trials of drugs or biologics, with at least 1 US study location, completed or terminated from January 1, 2007, through December 31, 2009 (allowing at least 7 years from trial completion for results reporting). We manually grouped trials into a sponsor-drug-condition trial set when the listed sponsor, drug, and condition appeared to be identical; we limited the analysis to a convenience sample of the first 96 sponsor-drug-condition trial sets identified. On July 25, 2017, we assessed the availability of results in PubMedcited publications and/or results posted in ClinicalTrials.gov based on methods used in prior research. 4 We also evaluated whether the drug was approved by the US Food and Drug Administration (FDA) for any use.
Results | Our sample consisted of 329 trials studying 86 drugs and representing 96 unique sponsor-drug-condition trial sets (eg, Amgen-sponsored trials of alendronate for osteoporosis). The median number of trials per set was 3 (range, 2-11).
The median proportion of trials in each set with results publicly available (in PubMed and/or ClinicalTrials.gov) was 100% (interquartile range, 62.5%-100%). Most trials used parallel assignment, double-blinding, randomization, and multiple sites and had more than 100 participants enrolled ( Discussion | ClinicalTrials.gov was a unique source of results for nearly one-quarter of sampled drug trials and more than onetenth of sampled sponsor-drug-condition trial sets. However, results remain unavailable in ClinicalTrials.gov or PubMed 7 or more years after study completion for nearly one-quarter of sampled drug trials and more than one-tenth of sampled sponsor-drug-condition trial sets. This study is limited by the convenience sampling approach, omission of unregistered trials, and lack of assessment of reporting content. Availabil 
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Antibiotic Therapy Duration in US Adults With Sinusitis
Sinusitis is the most common condition for which outpatient antibiotic therapy is prescribed in the United States. 1 Sinusitis antibiotic stewardship efforts have largely focused on whether to prescribe antibiotics and on the selection of appropriate antibiotics. 1,2 When antibiotics are indicated for the treatment of acute bacterial sinusitis, the Infectious Diseases Society of America evidence-based clinical practice guidelines recommend 5 to 7 days of therapy for patients with a low risk of antibiotic resistance who have a favorable response to initial therapy. 3 Guideline-concordant treatment duration may represent a stewardship opportunity. Our objective was to describe the duration of antibiotic therapy for acute sinusitis in adult outpatients.
Methods | We identified visits to physicians at which antibiotics were prescribed for sinusitis diagnoses in the 2016 National Disease and Therapeutic Index (IQVIA). The National Disease and Therapeutic Index is a 2-stage stratified cluster sample of drug therapies that is based on a random sample of US office-based physicians in private practice who report on all patient contacts for 2 randomly selected consecutive workdays. We included observations for visits by adults (≥18 years of age) to family practice, general practice, geriatrics, internal medicine, pediatrics, and emergency medicine physicians at which a new prescription for an oral antibiotic was given in association with an acute sinusitis diagnosis. We excluded visits associated with a diagnosis of chronic sinusitis, concurrent antibiotic prescriptions for other conditions, or missing data on duration of therapy. We generated estimates that accounted for the complex sample design with use of weighted analyses. We grouped antibiotics as penicillins (including amoxicillin-clavulanate), tetracyclines, fluoroquinolones, cephalosporins, azithromycin, or other. We categorized azithromycin separately because of its unique pharmacokinetic characteristics. We conducted a sensitivity analysis that included cases of unspecified as well as acute sinusitis. Statistical tests were conducted at the α = .05 level. We conducted all analyses using SAS, version 9.4 (SAS Institute Inc). The human subjects advisor from the National Center for Emerging and Zoonotic Infectious Diseases has determined that these data do not require institutional review board review.
Results | There were an estimated 3 696 976 visits (95% CI, 3 124 279-4 269 673) at which antibiotic therapy was prescribed for sinusitis that met our inclusion criteria. The median duration of therapy was 10.0 days (interquartile range, 7.0-10.0 days), and 69.6% (95% CI, 63.7%-75.4%) of therapies were prescribed for 10 days or longer (Table) . When azithromycin prescriptions were excluded, 91.5% of antibiotic courses (95% CI, 87.8%-95.2%) were 10 days or longer, 7.6% (95% CI, 4.1%-11.1%) were 7 days, and 0.5% (95% CI, 0.0%-1.6%) were 5 days.
Discussion | More than two-thirds of antibiotic courses and 91% of nonazithromycin antibiotic courses prescribed for the treatment of acute sinusitis in adults were 10 days or longer, even though the Infectious Diseases Society of America recommends 5 to 7 days of therapy for uncomplicated cases. 3 Notably, no penicillin or tetracycline prescriptions were for 5-day courses, and only 5% of antibiotic prescriptions were for 7-day courses of penicillins, tetracyclines, or fluoroquinolones. Although 7-to 10-day courses are recommended for patients at high risk or who have experienced failure of initial treatment, 3 it is unlikely that such cases represent most patients in our study. Earlier work has shown that 90% of patients with sinusitis that is treated with antibiotics do not require additional antibiotic therapy. 4 Shorter durations (3-7 days) of antibiotic therapy for sinusitis have been associated with similar outcomes and fewer drug-related adverse events compared with longer durations (6-10 days).
5
Greater than 20% of prescriptions were for a 5-day course of azithromycin, a course that clinicians and patients often find convenient. However, the Infectious Diseases Society of America explicitly recommends against the use of azithromycin for the treatment of sinusitis because of its known association with the development of drug resistance.
3 In addition, because of high and persistent concentrations of azithromycin in tissue, 5 days of azithromycin therapy approximates 10 days of erythromycin therapy; therefore,
